Table 1.
Baseline patient characteristics according to treatment arm
| Patient characteristics | Monotherapy etanercept (n = 15) | Combination therapy etanercept with fumarates (n = 18) |
|---|---|---|
| Gender, n | ||
| Males | 8 (53) | 14 (78) |
| Females | 7 (47) | 4 (22) |
| Mean age ± SD, years | 45±16 | 43±17 |
| Mean height ± SD, m | 1.72±0.13 | 1.77±0.11 |
| Mean BMI ± SD | 30±6* | 26±6* |
| PGA score, n | ||
| Moderate | 6 (40) | 13 (72) |
| Severe | 9 (60) | 5 (28) |
| Median PASI score | 14 [11, 21] | 12 [10,16] |
| Median DLQI score | 9 [5, 20] | 8 [3, 13] |
| Mean duration of psoriasis ± SD, years | 19 (10) | 22 (10) |
| History of psoriatic arthritis, n | 1 (7) | 5 (28) |
| Prior therapy, n | ||
| UVB/PUVA | 15 (93) | 17 (94) |
| Fumarates | 13 (87) | 11 (61) |
| Methotrexate | 13 (87) | 13 (72) |
| Cyclosporin | 4 (27) | 6 (33) |
| Acitretin | 6 (40) | 10 (56) |
| Biologic | 3 (20)* | 10 (56)* |
*
p < 0.05: statistically significantly different between monotherapy and combination group. Figures in parentheses are percentages, those in square brackets first and third quartiles.